Literature DB >> 27802977

Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?

Robin M Murray1, Diego Quattrone2, Sridhar Natesan2, Jim van Os2, Merete Nordentoft2, Oliver Howes2, Marta Di Forti2, David Taylor2.   

Abstract

Patients who recover from an acute episode of psychosis are frequently prescribed prophylactic antipsychotics for many years, especially if they are diagnosed as having schizophrenia. However, there is a dearth of evidence concerning the long-term effectiveness of this practice, and growing concern over the cumulative effects of antipsychotics on physical health and brain structure. Although controversy remains concerning some of the data, the wise psychiatrist should regularly review the benefit to each patient of continuing prophylactic antipsychotics against the risk of side-effects and loss of effectiveness through the development of supersensitivity of the dopamine D2 receptor. Psychiatrists should work with their patients to slowly reduce the antipsychotic to the lowest dose that prevents the return of distressing symptoms. Up to 40% of those whose psychosis remits after a first episode should be able to achieve a good outcome in the long term either with no antipsychotic medication or with a very low dose. © The Royal College of Psychiatrists 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27802977     DOI: 10.1192/bjp.bp.116.182683

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  44 in total

1.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

2.  Experiences of taking neuroleptic medication and impacts on symptoms, sense of self and agency: a systematic review and thematic synthesis of qualitative data.

Authors:  Jemima Thompson; Jacki L Stansfeld; Ruth E Cooper; Nicola Morant; Nadia E Crellin; Joanna Moncrieff
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2019-12-24       Impact factor: 4.328

3.  The long-term treatment of schizophrenia with antipsychotics: a perennial debate.

Authors:  W Wolfgang Fleischhacker
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

4.  Improving outcomes of first-episode psychosis: an overview.

Authors:  Paolo Fusar-Poli; Patrick D McGorry; John M Kane
Journal:  World Psychiatry       Date:  2017-10       Impact factor: 49.548

5.  The clinical characterization of the patient with primary psychosis aimed at personalization of management.

Authors:  Mario Maj; Jim van Os; Marc De Hert; Wolfgang Gaebel; Silvana Galderisi; Michael F Green; Sinan Guloksuz; Philip D Harvey; Peter B Jones; Dolores Malaspina; Patrick McGorry; Jouko Miettunen; Robin M Murray; Keith H Nuechterlein; Victor Peralta; Graham Thornicroft; Ruud van Winkel; Joseph Ventura
Journal:  World Psychiatry       Date:  2021-02       Impact factor: 49.548

6.  Association of Aripiprazole With the Risk for Psychiatric Hospitalization, Self-harm, or Suicide.

Authors:  François Montastruc; Rui Nie; Simone Loo; Soham Rej; Sophie Dell'Aniello; Joëlle Micallef; Samy Suissa; Christel Renoux
Journal:  JAMA Psychiatry       Date:  2019-04-01       Impact factor: 21.596

Review 7.  Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia.

Authors:  Susan F Sonnenschein; Anthony A Grace
Journal:  Neuropharmacology       Date:  2019-05-08       Impact factor: 5.250

8.  A 20-Year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia.

Authors:  Martin Harrow; Thomas H Jobe; Robert N Faull; Jie Yang
Journal:  Psychiatry Res       Date:  2017-06-22       Impact factor: 3.222

9.  Relegating Psychosis: Blood Work and "Routine Connection" in the Clozapine Clinic.

Authors:  Julia E H Brown
Journal:  Cult Med Psychiatry       Date:  2020-06

10.  30 Years on: How the Neurodevelopmental Hypothesis of Schizophrenia Morphed Into the Developmental Risk Factor Model of Psychosis.

Authors:  Robin M Murray; Vishal Bhavsar; Giada Tripoli; Oliver Howes
Journal:  Schizophr Bull       Date:  2017-10-21       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.